Adam Bagg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3194611/publications.pdf

Version: 2024-02-01

185	12,918	159585 30	23533 111
papers	citations	h-index	g-index

187	187	187	13629
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Germline POT1 variants can predispose to myeloid and lymphoid neoplasms. Leukemia, 2022, 36, 283-287.	7.2	17
2	Transcriptome and unique cytokine microenvironment of Castleman disease. Modern Pathology, 2022, 35, 451-461.	5.5	10
3	The disease course of Castleman disease patients with fatal outcomes in the <scp>ACCELERATE</scp> registry. British Journal of Haematology, 2022, , .	2.5	2
4	Clinical laboratory mutation analysis performed on aggressive B cell non-Hodgkin lymphoma patient biopsies.. Journal of Clinical Oncology, 2022, 40, e19561-e19561.	1.6	0
5	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology, 2021, 34, 20-31.	5.5	9
6	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. Modern Pathology, 2021, 34, 904-921.	5.5	11
7	Ionized Calcium Binding Adaptor Molecule 1 (IBA1). American Journal of Clinical Pathology, 2021, 156, 86-99.	0.7	9
8	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology, 2021, 34, 1358-1366.	5.5	8
9	VEXAS: a vivid new syndrome associated with vacuoles in various hematopoietic cells. Blood, 2021, 137, 3690-3690.	1.4	7
10	Classic Hodgkin Lymphoma â€“ Old Disease, New Directions: An Update on Pathology, Molecular Features and Biological Prognostic Markers. Acta Medica Academica, 2021, 50, 110.	0.8	2
11	Myeloid/lymphoid neoplasms with FLT3 rearrangement. Modern Pathology, 2021, 34, 1673-1685.	5.5	21
12	Transitioning T-Cell Clonality Testing to High-Throughput Sequencing. Journal of Molecular Diagnostics, 2021, 23, 781-783.	2.8	3
13	18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Molecular Imaging and Biology, 2021, 23, 818-826.	2.6	8
14	Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML. Cancer Genetics, 2021, 256-257, 68-76.	0.4	2
15	Anemia in a young Guinean male. Clinical Case Reports (discontinued), 2021, 9, e04593.	0.5	0
16	Evaluation of Scopio Labs X100 Full Field PBS: The first highâ€resolution full field viewing of peripheral blood specimens combined with artificial intelligenceâ€based morphological analysis. International Journal of Laboratory Hematology, 2021, 43, 1408-1416.	1.3	19
17	Laboratory Workup of Lymphoma in Adults. American Journal of Clinical Pathology, 2021, 155, 12-37.	0.7	9
18	Orbital and Ocular Adnexal Manifestations of Adult T-Cell Leukemia/Lymphoma: a Case Report and Systematic Review. Ophthalmic Plastic and Reconstructive Surgery, 2021, 37, 201-211.	0.8	4

#	Article	IF	Citations
19	Laboratory Workup of Lymphoma in Adults: Guideline From the American Society for Clinical Pathology and the College of American Pathologists. Archives of Pathology and Laboratory Medicine, 2021, 145, 269-290.	2.5	9
20	Mutational Analysis Reinforces the Diagnosis of Nodal Marginal Zone Lymphoma With Robust PD1-positive T-Cell Hyperplasia. American Journal of Surgical Pathology, 2021, 45, 143-145.	3.7	1
21	Leukemia Cutis With Histopathologic and Immunophenotypic Features Resembling S100-Negative CD1a-Positive Cutaneous Histiocytosis. American Journal of Dermatopathology, 2021, 43, 574-575.	0.6	2
22	Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease. Blood, 2021, 138, 1623-1623.	1.4	2
23	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	5.5	9
24	Performance Evaluation Study of a Novel Digital Microscopy System for the Quantitative Analysis of Bone Marrow Aspirates. Blood, 2021, 138, 4000-4000.	1.4	1
25	Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease. Blood, 2021, 138, 1622-1622.	1.4	0
26	Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation â€“ diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib. Leukemia and Lymphoma, 2020, 61, 450-454.	1.3	2
27	Conjunctival Pediatric-Type Follicular Lymphoma. Ophthalmic Plastic and Reconstructive Surgery, 2020, 36, e46-e49.	0.8	6
28	Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges. International Journal of Laboratory Hematology, 2020, 42, 671-684.	1.3	7
29	A 2020 Vision Into Hodgkin Lymphoma Biology. Advances in Anatomic Pathology, 2020, 27, 269-277.	4.3	3
30	Aplastic anemia in a patient with CVID due to NFKB1 haploinsufficiency. Journal of Physical Education and Sports Management, 2020, 6, a005769.	1.2	3
31	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. American Journal of Hematology, 2020, 95, 1553-1561.	4.1	18
32	Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia. British Journal of Haematology, 2020, 191, 935-938.	2.5	3
33	Coactivation of NF-ÎºB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. Blood, 2020, 135, 108-120.	1.4	14
34	An atypical systemic form of chronic active EBV infection. Leukemia and Lymphoma, 2020, 61, 3030-3032.	1.3	0
35	Comparison of therapyâ€related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. American Journal of Hematology, 2020, 95, 799-808.	4.1	26
36	Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. International Journal of Laboratory Hematology, 2020, 42, 418-422.	1.3	21

#	Article	IF	Citations
37	Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms. Blood, 2020, 136, 2-4.	1.4	1
38	Genetic studies in the evaluation of myeloproliferative neoplasms. Seminars in Hematology, 2019, 56, 7-14.	3.4	4
39	Falsely Increased Plasma Lactate Dehydrogenase without Hemolysis Following Transport through Pneumatic Tube System. journal of applied laboratory medicine, The, 2019, 4, 433-438.	1.3	8
40	Longitudinal targeted nextâ€generation sequencing in a patient with acute myeloid leukaemia. British Journal of Haematology, 2019, 186, 801-801.	2.5	0
41	Cyclin D1 expression and novel mutational findings in RosaiâÐorfman disease. British Journal of Haematology, 2019, 186, 837-844.	2.5	31
42	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Modern Pathology, 2019, 32, 1373-1385.	5.5	25
43	High-throughput sequencing of the T-cell receptor Î² chain gene distinguishes 2 subgroups of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2019, 80, 1148-1150.e1.	1.2	4
44	Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia. PLoS ONE, 2019, 14, e0215021.	2.5	5
45	Myeloid neoplasm with eosinophilia and PCM1-JAK2 associated with acute promyelocytic leukemia with PML-RARA. Leukemia and Lymphoma, 2019, 60, 2299-2303.	1.3	2
46	Rosai-Dorfman Disease of the Breast With Variable IgG4+ Plasma Cells. American Journal of Surgical Pathology, 2019, 43, 1653-1660.	3.7	17
47	Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances, 2019, 3, 1540-1545.	5.2	44
48	Isolated Langerhans Cell Histiocytosis of the Lacrimal Gland in Conjunction With Mucosa-Associated Lymphoid Tissue Lymphoma and Elevated IgG4 Plasma Cells. Ophthalmic Plastic and Reconstructive Surgery, 2019, 35, e92-e94.	0.8	1
49	Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Modern Pathology, 2019, 32, 490-498.	5.5	50
50	FBXW7 mutations in acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 1601-1602.	1.3	1
51	Expedited Analysis and Reporting of Multiple Mutations that Modify Medical Management of Myeloid Malignancies. Journal of Molecular Diagnostics, 2019, 21, 13-15.	2.8	0
52	Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma. Journal of Clinical Pathology, 2018, 71, 814-820.	2.0	26
53	A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. Modern Pathology, 2018, 31, 873-880.	5.5	3
54	Next-Generation Sequencing for Lymphomas. Journal of Molecular Diagnostics, 2018, 20, 163-165.	2.8	3

#	Article	IF	Citations
55	T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas. American Journal of Clinical Pathology, 2018, 149, 164-171.	0.7	23
56	Myeloproliferative neoplasms with concurrent BCRâ€“ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Modern Pathology, 2018, 31, 690-704.	5.5	35
57	JAK2 V617Fâ€positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. British Journal of Haematology, 2018, 182, 78-85.	2.5	22
58	Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351. Blood, 2018, 132, 4785-4785.	1.4	3
59	Classical Hodgkin Lymphoma Patients Have an Increased Incidence of Idiopathic Acquired Aplastic Anemia. Blood, 2018, 132, 5098-5098.	1.4	0
60	Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. Blood, 2018, 132, 1491-1491.	1.4	0
61	International, evidence-based consensus diagnostic criteria for HHV-8â€“negative/idiopathic multicentric Castleman disease. Blood, 2017, 129, 1646-1657.	1.4	381
62	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica, 2017, 102, 1352-1360.	3.5	62
63	NPM1 for MRD? Droplet Like It's Hot!. Journal of Molecular Diagnostics, 2017, 19, 498-501.	2.8	6
64	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38 chronic myelomonocytic leukemia. Modern Pathology, 2017, 30, 1213-1222.	5.5	52
65	Molecular Malfeasance Mediating Myeloid Malignancies: The Genetics of Acute Myeloid Leukemia. Methods in Molecular Biology, 2017, 1633, 1-17.	0.9	3
66	Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22). American Journal of Clinical Pathology, 2017, 147, 411-419.	0.7	6
67	Clonal Replacement Underlies Spontaneous Remission in Paroxysmal Nocturnal Haemoglobinuria. British Journal of Haematology, 2017, 176, 487-490.	2.5	20
68	BRAF kinase domain mutations in de novo acute myeloid leukemia with monocytic differentiation. Leukemia and Lymphoma, 2017, 58, 743-745.	1.3	9
69	A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. PLoS ONE, 2016, 11, e0153016.	2.5	10
70	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Modern Pathology, 2016, 29, 854-864.	5.5	104
71	FLT3Inhibitorâ€“Associated Neutrophilic Dermatoses. JAMA Dermatology, 2016, 152, 480.	4.1	25
72	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets. Leukemia and Lymphoma, 2016, 57, 1991-2013.	1.3	26

#	Article	IF	Citations
73	Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case report. Biomarker Research, 2016, 4, 14.	6.8	4
74	The cytological features of <scp>CAR</scp>(T) cells. British Journal of Haematology, 2016, 175, 366-366.	2.5	11
75	B-cells behaving badly II: A better basis to behold belligerence in aggressive B-cell lymphomas. Pathology, 2016, 48, S9.	0.6	0
76	Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells. Blood, 2016, 128, 766-766.	1.4	9
77	An extremely indolent T-cell leukemia: an 18-year follow-up. Journal of Community and Supportive Oncology, 2016, 14, 76-78.	0.1	4
78	Acute promyelocytic leukemia presenting as a paraspinal mass. Journal of Community and Supportive Oncology, 2016, 14, 126-129.	0.1	6
79	Mutational Shift in FLT3 and NPM1-Positive Acute Myeloid Leukemia (AML) Relative to Therapy and Disease Progression. Blood, 2016, 128, 2866-2866.	1.4	0
80	NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features. Haematologica, 2015, 100, e412-e414.	3.5	21
81	Chronic lymphocytic leukemia with a t(8;14)(q24;q32): <scp>FISH</scp>ing catches a (sheepish) red herring. American Journal of Hematology, 2015, 90, 1187-1188.	4.1	0
82	Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm. Cancer Genetics, 2015, 208, 625-629.	0.4	8
83	Multifocal Mantle Cell Lymphoma In Situ in the Setting of a Composite Lymphoma. American Journal of Clinical Pathology, 2015, 143, 274-282.	0.7	5
84	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 2015, 7, 303ra139.	12.4	1,402
85	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. New England Journal of Medicine, 2015, 373, 1040-1047.	27.0	511
86	De novo acute myeloid leukemia with 20â€“29% blasts is less aggressive than acute myeloid leukemia with â‰¥30% blasts in older adults: a <scp>B</scp>one <scp>M</scp>arrow <scp>P</scp>athology <scp>G</scp>roup study. American Journal of Hematology, 2014, 89, E193-9.	4.1	22
87	Hodgkin Lymphoma. Advances in Anatomic Pathology, 2014, 21, 12-25.	4.3	21
88	Genetics of Diffuse Large B-Cell Lymphoma. Cancer Journal (Sudbury, Mass), 2014, 20, 43-47.	2.0	4
89	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood, 2014, 123, 2645-2651.	1.4	192
90	Automated screening for myelodysplastic syndromes through analysis of complete blood count and cell population data parameters. American Journal of Hematology, 2014, 89, 369-374.	4.1	30

#	Article	IF	Citations
91	Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica, 2014, 99, 821-829.	3.5	61
92	Microsphere-Based Multiplex Analysis of DNA Methylation in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2014, 16, 207-215.	2.8	9
93	The Genetic Basis and Expanding Role of Molecular Analysis in the Diagnosis, Prognosis, and Therapeutic Design for Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2014, 16, 145-158.	2.8	32
94	Next-generation sequencing to identify mutations that may predict outcome after allogeneic stem cell transplantation for AML.. Journal of Clinical Oncology, 2014, 32, 7043-7043.	1.6	1
95	Development and implementation of a custom integrated database with dashboards to assist with hematopathology specimen triage and traffic. Journal of Pathology Informatics, 2014, 5, 29.	1.7	7
96	Predicting prognosis in patients with acute myeloid leukemia: The role of next-generation sequencing and mutational profiling.. Journal of Clinical Oncology, 2014, 32, 7068-7068.	1.6	0
97	Next Generation Mutational Profiling Improves Prognostication in Younger Patients with Acute Myeloid Leukemia. Blood, 2014, 124, 1032-1032.	1.4	0
98	Immunosuppressive and immunomodulatory therapy-associated lymphoproliferative disorders. Seminars in Diagnostic Pathology, 2013, 30, 102-112.	1.5	34
99	Molecular Diagnostics of Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2013, 15, 27-30.	2.8	2
100	Hereditary elliptocytosis. Blood, 2013, 121, 3066-3066.	1.4	6
101	Development of an Integrated Database and Dashboard for Bone Marrow Specimen Triage. American Journal of Clinical Pathology, 2013, 140, A067-A067.	0.7	0
102	Î±-Hemoglobin-stabilizing Protein Is a Sensitive and Specific Marker of Erythroid Precursors. American Journal of Surgical Pathology, 2012, 36, 1538-1547.	3.7	18
103	In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica, 2012, 97, 270-278.	3.5	146
104	Molecular-Based Classification of Acute Myeloid Leukemia and Its Role in Directing Rational Therapy. Molecular Diagnosis and Therapy, 2012, 16, 357-369.	3.8	10
105	Molecular genetic characterization of lymphoma: Application to cytology diagnosis. Diagnostic Cytopathology, 2012, 40, 542-555.	1.0	21
106	A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia. Blood, 2012, 120, 3576-3576.	1.4	4
107	Diverse Histopathologic and Molecular Responses of Acute Myeloid Leukemia to the FLT3 Inhibitor Quizartinib (AC220). Blood, 2012, 120, 885-885.	1.4	0
108	Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study. Blood, 2012, 120, 3847-3847.	1.4	0

#	Article	IF	Citations
109	T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Science Translational Medicine, 2011, 3, 95ra73.	12.4	2,006
110	Acute Myeloid Leukemia: Conventional Cytogenetics, FISH, and Moleculocentric Methodologies. Clinics in Laboratory Medicine, 2011, 31, 659-686.	1.4	14
111	Making a Meal of Multiple Mutations in Acute Myeloid Malignancies. Journal of Molecular Diagnostics, 2011, 13, 605-608.	2.8	0
112	Chimeric Antigen Receptorâ€"Modified T Cells in Chronic Lymphoid Leukemia. New England Journal of Medicine, 2011, 365, 725-733.	27.0	3,067
113	Therapy-associated Lymphoid Proliferations. Advances in Anatomic Pathology, 2011, 18, 199-205.	4.3	10
114	Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes. Expert Review of Molecular Diagnostics, 2011, 11, 361-366.	3.1	9
115	A Comparative Analysis of Molecular Genetic and Conventional Cytogenetic Detection of Diagnostically Important Translocations in More Than 400 Cases of Acute Leukemia, Highlighting the Frequency of False-Negative Conventional Cytogenetics. American Journal of Clinical Pathology, 2011, 135, 921-928.	0.7	28
116	Successful treatment of angioimmunoblastic T-cell lymphoma with the retinoid X receptor agonist, bexarotene. Leukemia and Lymphoma, 2011, 52, 1815-1817.	1.3	2
117	Transient Blood Transfusion Reaction Masquerading As a Post-Transplantation Lymphoproliferative Disorder Mimicking Acute Leukemia Cutis. Journal of Clinical Oncology, 2011, 29, e751-e753.	1.6	4
118	Intravascular Large B-Cell Lymphoma: A Mimicker of Many Maladies and a Difficult and Often Delayed Diagnosis. Journal of Clinical Oncology, 2011, 29, e138-e140.	1.6	20
119	Crystalâ€storing histiocytosis in plasma cell myeloma. American Journal of Hematology, 2010, 85, 444-445.	4.1	8
120	Multiple cutaneous monoclonal Bâ€cell proliferations as harbingers of systemic angioimmunoblastic Tâ€cell lymphoma. Journal of Cutaneous Pathology, 2010, 37, 777-786.	1.3	18
121	The Basis and Rational Use of Molecular Genetic Testing in Mature B-cell Lymphomas. Advances in Anatomic Pathology, 2010, 17, 333-358.	4.3	7
122	Coexisting Follicular and Mantle Cell Lymphoma With Each Having an In Situ Component. American Journal of Clinical Pathology, 2010, 133, 584-591.	0.7	58
123	Isolated Bowel Relapse in Acute Promyelocytic Leukemia: An Unusual Site of Extramedullary Recurrence. Journal of Clinical Oncology, 2010, 28, e550-e553.	1.6	11
124	Molecular diagnosis of acute myeloid leukemia. Expert Review of Molecular Diagnostics, 2010, 10, 993-1012.	3.1	15
125	Diagnostic challenges in the myelodysplastic syndromes: the current and future role of genetic and immunophenotypic studies. Expert Opinion on Medical Diagnostics, 2009, 3, 275-291.	1.6	0
126	A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia. Clinical Cancer Research, 2009, 15, 6732-6739.	7.0	97

#	Article	IF	Citations
127	Extracavitary primary effusion lymphoma in an HIV-positive patient with Kaposi sarcoma-associated. Community Oncology, 2009, 6, 523-525.	0.2	1
128	Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. American Journal of Hematology, 2008, 83, 296-302.	4.1	30
129	The Evolution of Molecular Genetic Pathology. Journal of Molecular Diagnostics, 2008, 10, 480-483.	2.8	14
130	Nucleophosmin (NPM1) Mutations in Acute Myeloid Leukemia: An Ongoing (Cytoplasmic) Tale of Dueling Mutations and Duality of Molecular Genetic Testing Methodologies. Journal of Molecular Diagnostics, 2008, 10, 198-202.	2.8	21
131	Malleable Immunoglobulin Genes and Hematopathology â€“ The Good, the Bad, and the Ugly. Journal of Molecular Diagnostics, 2008, 10, 396-410.	2.8	13
132	Sudden Extramedullary T-Lymphoblastic Blast Crisis in Chronic Myelogenous Leukemia. American Journal of Clinical Pathology, 2008, 129, 639-648.	0.7	19
133	A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Clinical Cancer Research, 2008, 14, 5619-5625.	7.0	32
134	A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Blood, 2008, 112, 4040-4040.	1.4	0
135	A Robust Xenotransplantation Model for Acute Myeloid Leukemia. Blood, 2008, 112, 2939-2939.	1.4	0
136	Recent insights into the biology of Hodgkin lymphoma: unraveling the mysteries of the Reedâ€“Sternberg cell. Expert Review of Molecular Diagnostics, 2007, 7, 805-820.	3.1	11
137	Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. Cancer Biology and Therapy, 2007, 6, 18-21.	3.4	9
138	Primary cardiac lymphoma: Utility of multimodality imaging in diagnosis and management. Cancer Biology and Therapy, 2007, 6, 1867-1870.	3.4	17
139	Toward a Therapeutically Relevant, Molecularly Based Classification of Lymphoma. American Journal of Clinical Pathology, 2007, 127, 12-14.	0.7	0
140	Lineage Ambiguity, Infidelity, and Promiscuity in Immunophenotypically Complex Acute Leukemias. American Journal of Clinical Pathology, 2007, 128, 545-548.	0.7	10
141	CD79a Is Heterogeneously Expressed in Neoplastic and Normal Myeloid Precursors and Megakaryocytes in an Antibody Cloneâ€“Dependent Manner. American Journal of Clinical Pathology, 2007, 128, 306-313.	0.7	32
142	Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders. Journal of Molecular Diagnostics, 2007, 9, 134-143.	2.8	121
143	IgÎ²(CD79b)mRNA expression in chronic lymphocytic leukaemia cells correlates with immunoglobulin heavy chain gene mutational status but does not serve as an independent predictor of clinical severity. American Journal of Hematology, 2007, 82, 712-720.	4.1	4
144	Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. British Journal of Haematology, 2007, 139, 351-362.	2.5	249

#	Article	IF	Citations
145	A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma. Cancer Genetics and Cytogenetics, 2007, 172, 45-53.	1.0	21
146	An Alternative SplicedRNASELVariant in Peripheral Blood Leukocytes. Journal of Interferon and Cytokine Research, 2006, 26, 820-826.	1.2	5
147	Immunoglobulin and T-Cell Receptor Gene Rearrangements: Minding Your B's and T's in Assessing Lineage and Clonality in Neoplastic Lymphoproliferative Disorders. Journal of Molecular Diagnostics, 2006, 8, 426-429.	2.8	21
148	Large B-Cell Lymphoma Masquerading As Acute Leukemia. Journal of Clinical Oncology, 2006, 24, 1950-1951.	1.6	6
149	Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.. Blood, 2006, 108, 3982-3982.	1.4	18
150	A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.. Blood, 2006, 108, 1955-1955.	1.4	0
151	Flow-cytometric analysis of peripheral blood neutrophils: A simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. American Journal of Hematology, 2005, 79, 243-245.	4.1	22
152	Expanded Populations of Surface Membrane Immunoglobulin Light Chainâ€“Negative B Cells in Lymph Nodes Are Not Always Indicative of B-Cell Lymphoma. American Journal of Clinical Pathology, 2005, 124, 143-150.	0.7	23
153	Recurrence of Nodal Diffuse Large B-Cell Lymphoma as Intravascular Large B-Cell Lymphoma: Is an Intravascular Component at Initial Diagnosis Predictive?. Archives of Pathology and Laboratory Medicine, 2005, 129, 391-394.	2.5	29
154	Philadelphia Chromosome (Phâ€™) Negative, MLL-Rearranged AML Arising in a Patient Treated with Imatinib for CML.. Blood, 2005, 106, 4880-4880.	1.4	0
155	Molecular diagnosis in lymphoma. Psychophysiology, 2005, 4, 313-23.	1.1	4
156	Role of molecular studies in the classification of lymphoma. Expert Review of Molecular Diagnostics, 2004, 4, 83-97.	3.1	14
157	Reactive versus neoplastic lymphoid follicles: proliferation and death versus quiescence and staying alive. British Journal of Haematology, 2004, 126, 757-757.	2.5	1
158	Molecular diagnosis in lymphoma. Current Oncology Reports, 2004, 6, 369-379.	4.0	3
159	Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood, 2004, 103, 3300-3302.	1.4	141
160	Multiplex RT-PCR for the Detection of Leukemia-Associated Translocations. Journal of Molecular Diagnostics, 2003, 5, 231-236.	2.8	37
161	Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics and Metabolism, 2003, 80, 148-158.	1.1	1,309
162	Clinical applications of molecular genetic testing in hematologic malignancies: Advantages and limitations. Human Pathology, 2003, 34, 352-358.	2.0	11

#	Article	IF	Citations
163	Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 2003, 101, 3875-3876.	1.4	415
164	Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood, 2003, 102, 972-980.	1.4	432
165	Preexisting Immunity to Adenovirus in Rhesus Monkeys Fails To Prevent Vector-Induced Toxicity. Journal of Virology, 2002, 76, 5711-5719.	3.4	80
166	Aggressive Epstein-Barr Virus-Associated, CD8+, CD30+, CD56+, Surface CD3âˆ', Natural Killer (NK)-Like Cytotoxic T-Cell Lymphoma. American Journal of Surgical Pathology, 2002, 26, 111-118.	3.7	23
167	Chronic Myeloid Leukemia. Journal of Molecular Diagnostics, 2002, 4, 1-10.	2.8	25
168	T Cell Receptor Î³-Chain Gene Polymerase Chain Reaction to Diagnose Central Nervous System Involvement by Cutaneous T Cell Lymphoma. Journal of Molecular Diagnostics, 2002, 4, 118-120.	2.8	1
169	Immunoglobulin Heavy Chain Gene Analysis in Lymphomas. Journal of Molecular Diagnostics, 2002, 4, 81-89.	2.8	95
170	Unusual Hematologic Malignancies. Journal of Clinical Oncology, 2002, 20, 3737-3739.	1.6	3
171	Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: Is this T-cell chronic lymphocytic leukemia?. American Journal of Hematology, 2002, 71, 224-226.	4.1	27
172	CD5-Negative, CD10-Negative small B-cell leukemia: Variant of chronic lymphocytic leukemia or a distinct entity?. American Journal of Hematology, 2002, 71, 306-310.	4.1	25
173	Evaluation of T Cell Receptor Testing in Lymphoid Neoplasms. Journal of Molecular Diagnostics, 2001, 3, 133-140.	2.8	39
174	Clinical syndromes of transformation in clonal hematologic disorders. American Journal of Medicine, 2001, 111, 480-488.	1.5	4
175	SHP-1 Expression by Malignant Small B-Cell Lymphomas Reflects the Maturation Stage of Their Normal B-Cell Counterparts. American Journal of Surgical Pathology, 2001, 25, 949-955.	3.7	17
176	Chronic myelogenous leukemia: Laboratory diagnosis and monitoring. Genes Chromosomes and Cancer, 2001, 32, 97-111.	2.8	53
177	Commentary Minimal Residual Disease: How Low Do We Go?. Molecular Diagnosis and Therapy, 2001, 6, 155-160.	1.1	8
178	Posttherapy Surveillance of B-Cell Precursor Acute Lymphoblastic Leukemia: Value of Polymerase Chain Reaction and Limitations of Flow Cytometry. American Journal of Clinical Pathology, 1999, 111, 759-766.	0.7	23
179	Development of rheumatoid arthritis after treatment of large granular lymphocyte leukemia with deoxycoformycin. , 1998, 57, 253-257.		10
180	Molecular genetic biomarkers in hematological malignancies. Journal of Cellular Biochemistry, 1996, 63, 165-171.	2.6	1

#	Article	IF	Citations
181	Identification of the chimeric protein product of the CBFBâ€MYH11 fusion gene in inv(16) leukemia cells. Genes Chromosomes and Cancer, 1996, 16, 77-87.	2.8	61
182	Temporal association of marrow eosinophilia with inversion of chromosome 16 in recurrent blast crises of chronic myelogenous leukemia. Cancer Genetics and Cytogenetics, 1992, 62, 134-139.	1.0	21
183	Circulating monotypic B-cells in multiple myeloma: association with lambda paraproteins. British Journal of Haematology, 1989, 72, 167-172.	2.5	14
184	Precursor T-cell lymphoma associated with human immunodeficiency virus type 1 (HIV-1) infection. First reported case. Cancer, 1989, 64, 39-42.	4.1	17
185	The Routine Diagnostic Utility of Immunoglobulin and T-Cell Receptor Gene Rearrangements in Lymphoproliferative Disorders. American Journal of Clinical Pathology, 1989, 91, 633-638.	0.7	21